How AstraZeneca’s 1Q18 Shook Out



A look at AstraZeneca

Headquartered in London, AstraZeneca (AZN) is a pharmaceutical company with operations in over 100 countries. The company is involved in the research, development, and manufacture of drugs for both primary care and specialty care.

The above chart compares AstraZeneca’s revenues and EPS (earnings per share) since 1Q16 and estimates for its 1Q18.

Article continues below advertisement

Stock price performance

AstraZeneca stock has fallen ~1.2% in 1Q18, and its stock has risen ~2.1% YTD (year-to-date) as of April 6, 2018.

Analysts’ recommendations

Analysts expect AZN to return ~10.4% over the next 12 months. Analysts’ recommendations show a 12-month target price of $39.09 on the stock compared to its price of $35.42 on April 6, 2018.

Six analysts are tracking AstraZeneca’s ADR (American depositary receipt). Four of them recommend “buys,” while two recommend “holds.” There are 31 analysts tracking AstraZeneca stock. Of these, nine recommend “strong buys,” 14 recommend “buys,” five recommend “holds,” and three recommend “sells.” The consensus rating for AstraZeneca stock is 2.06, which represents a strong buy for value investors and a moderate buy for long-term growth investors.

Analysts’ revenue estimates

AstraZeneca’s revenue has mainly been driven by the strong performance of growth platforms in its Respiratory segment, new products in its Cardiovascular and Metabolic Diseases segment (including Brilinta and diabetes products), new products in its Oncology segment (including Iressa US, Lynparza, Tagrisso, and Imfinzi), and its regional sales in emerging markets and Japan.

Analysts expect AZN to see revenue of $5.5 billion in 1Q18, a ~2.3% rise compared to 1Q17. They expect AZN to report EPS of $0.92 in 1Q18.

The Vanguard FTSE All-World ex-US ETF (VEU) holds 7.4% of its total investments in healthcare companies. VEU holds 0.4% in AstraZeneca, 0.4% in GlaxoSmithKline (GSK), 0.4% in Sanofi (SNY), and 0.8% in Novartis AG (NVS).

Check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!


More From Market Realist